Taken together, the data derived from genetic and pharmacological approaches in pre-clinical murine GvHD models clearly indicate that Syk plays an important role in GvHD pathophysiology.

Against this backdrop, investors have an opportunity to invest in stable robotics stocks, Stryker Corporation (SYK), Fanuc Corporation (FANUY), and UiPath Inc. (PATH), which are at the forefront of ...

Below is Validea's guru fundamental report for STRYKER CORP (SYK). Of the 22 guru strategies we follow, SYK rates highest using our P/B Growth Investor model based on the published strategy of ...

For anyone who wants to understand Stryker's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit was reduced by US$1.3b due to unusual ...

Stryker Corporation’s SYK shares closed the trading session at $385.18 on Friday, 5.2% below its 52-week high of $406.19 reached on Jan. 28, 2025. In the past six months, SYK has gained 13%.

Below is Validea's guru fundamental report for STRYKER CORP (SYK). Of the 22 guru strategies we follow, SYK rates highest using our P/B Growth Investor model based on the published strategy of ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

Gene-engineered immune cell therapies have partially transformed cancer treatment, as exemplified by the use of chimeric antigen receptor (CAR)-T cells in certain hematologic malignancies. However, ...

Direct activation of the human phospholipase C-γ isozymes (PLC-γ1, -γ2) by tyrosine phosphorylation is fundamental to the control of diverse biological processes, including chemotaxis, platelet ...